| Chemical Properties | Back Directory | [storage temp. ]
Store at -20°C | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; DMSO:PBS(pH 7.2) (1:2): 0.25 mg/ml; Ethanol: 5 mg/ml; Methanol: 1 mg/ml | [form ]
A crystalline solid |
| Hazard Information | Back Directory | [Description]
(±)-WIN 55,212 is a racemic mixture of the cannabinoid (CB) receptor 1 (CB1) and CB2 agonist (+)-WIN 55,212-2 and the CB2 neutral antagonist (?)-WIN 55,212-3 .1 It inhibits electrically induced contractions in mouse vas deferens preparations (IC50 = 0.006 μM) and reduces prostaglandin (PG) synthesis by 35% in mouse brain microsomes when used at a concentration of 30 μM.2 (±)-WIN 55,212 decreases acetylcholine-induced writhing in mice with an ED50 value of 0.25 mg/kg. It induces hypolocomotion, analgesia, hypothermia, and catalepsy in mice (ED50s = 1.09, 0.5, 3.01 and 6.8 mg/kg, respectively).3 | [References]
1. Savinainen, J.R., Kokkola, T., Salo, O.M.H., et al. Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor Br. J. Pharmacol. 145,636-645(2005).
2. D'Ambra, T.E., Estep, K.G., Bell, M.R., et al. Conformationally restrained analogues of pravadoline: Nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor J. Med. Chem. 35,124-135(1992).
3. Fan, F., Compton, D.R., Ward, S., et al. Development of cross-tolerance between Δ9-tetrahydrocannabinol, CP 55,940 and WIN 55,212 J. Pharmacol. Exp. Ther. 271(3),1383-1390(1994). |
|
|